The pharmacokinetics of HIV protease inhibitor combinations

Current Opinion in Infectious Diseases

Volumn 18, Issue 1, 2005, Pages 1-7

  Boffito, Marta ^a   Maitland, Desmond ^a   Samarasinghe, Yohan ^a   Pozniak, Anton ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Double boosting strategies; Protease inhibitor boosting; Salvage therapy settings

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

AREA UNDER THE CURVE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; NAUSEA; REVIEW; VIRUS INHIBITION; DRUG COMBINATION;

DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS;

EID: 17544368645     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200502000-00002     Document Type: Review

References (46)

1. Van Heeswijk RP, Veldkamp A, Mulder JW, et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 2001; 6:201-229.
2. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2:105-113.
3. Craig JC, Duncan IB, Hockley D, et al. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991; 16:295-305.
4. Dam E, Rochas S, Faudon JL, et al. Synergistic activity of lopinavir and saquinavir on protease inhibitor-resistant HIV-1 [abstract]. In: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2004; San Francisco. Alexandria: Foundation for Retrovirology and Human Health; 2004. Abstract 622.
5. Hammer SM, Vaida F, Bennett KK, et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 2002; 288:169-180.
6. Staszewski S, Dauer B, Carlebach A, et al. The LOPSAQ salvage study: 48 week analysis of the full cohort treated with lopinavir (LPV/r) plus saquinavir (SQV) without any additional antiretroviral (ART) therapy [abstract]. In: Program and Abstracts of the XV International AIDS Conference, 11-16 July 2004; Bangkok. Geneva: International AIDS Society; 2004. Abstract B10840.
7. Gerber JG. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. Clin Infect Dis 2000; (Suppl 2): S123-S129.
8. Seminari E, Schira G, Guffanti M, et al. Pharmacokinetics (PK) of saquinavir-hard gel capsules (SQV-hgc) when combined with atazanavir (ATV) as once a day combination (1200/400) in highly experienced HIV-positive patients [abstract]. In: Program and Abstracts of the Second International AIDS Society Conference on HIV Pathogenesis and Treatment, 13-16 July 2003; Paris. London: International Medical Press; 2003. Abstract 847.
9. Canta F, Marrone R, Gonzalez de Requena D, et al. Pharmacokinetics of atazanavir (ATV) alone and coadministered with saquinavir hard gel capsules (SQVhg) once daily [abstract]. In: Program and abstracts of the Fifth International Workshop on Clinical Pharmacology of HIV Therapy. 11-13 March 2004; Rome. Utrecht: Virology Education; 2004. Abstract 4.21.
10. Guffanti M, De Pascalis CR, Seminari E, et al. Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pretreated HIV-positive patients. AIDS 2003; 17:2669-2671.
11. Guffanti M, Villani P, Seminari E, et al. Atazanavir (ATV) pharmacokinetics when combined with amprenavir (APV) in highly experienced HIV-positive patients [abstract]. In: Program and Abstracts of the Fifth International Workshop on Clinical Pharmacology of HIV Therapy, 11-13 March 2004; Rome. Utrecht: Virology Education; 2004. Abstract 4.10.
12. Boffito M, Moyle GJ. Can we boost enough without ritonavir? AIDS Read 2004; 14:229-230.
13. Smith GHR, Kline MB, Murphy T, et al. Double, boosted salvage therapy with lopinavir (LOP)/ritonavir (RIT) and saquinavir-sgc (SQR) in HIV-1 infected patients having failed 3 antiretroviral classes [abstract]. In: Proceedings of the XIV International AIDS Conference, 7-12 July 2002; Barcelona. Geneva: International AIDS Society; 2002. Abstract TuPeB4547.
14. Zala C, Patterson P, Coll P, et al. Virological response and safety at 48 weeks of double boosted protease inhibitors with lopinavir/r plus either saquinavir or amprenavir in heavily pretreated HIV infected patients [abstract]. In: Proceedings of the XIV International AIDS Conference, 7-12 July 2002; Barcelona. Geneva: International AIDS Society; 2002. Abstract TuPeB4492.
15. Hellinger J, Morris AB, Piscitelli S, et al. Pilot study of saquinavir-sgc (Fortovase, SQV) 1000-mg twice daily and lopinavir/ritonavir (Kaletra, LPV/r) in protease inhibitor experienced HIV+ individuals: dose escalation and combined normalized inhibitory quotient (cNIQ) [abstract]. In: Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections, 24-28 February 2002; Seattle. Alexandria: Foundation for Retrovirology and Human Health; 2002. Abstract 451-W.
16. Stephan C, Hentig N, Kourbeti I, et al. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 2004; 18:503-508. This well presented pharmacokinetic study showed the lack of a drug-drug interaction when coadministering saquinavir and lopinavir/ritonavir
17. th International Workshop on Clinical Pharmacology of HIV Therapy. 11-13 March 2004; Rome. Utrecht: Virology Education; 2004. Abstract 6.4.
18. Boffito M, Kurowski M, Kruse G, et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18: 1291-1297. This well performed pharmacokinetic study showed for the first time the favourable and unexpected interactions between saquinavir/atazanavir/ ritonavir all administered once daily to HIV-infected patients.
19. Kilby JM, Hill A, Buss N. The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects. HIV Med 2002; 3:97-104.
20. von Hentig NH, Mueller A, Haberl A, et al. The ATSAQ-1 cohort study: Pharmacokinetic interactions of atazanavir (AZV) and saquinavir (SQV) in a ritonavir (RW) boosted protease inhibitor therapy regimen [abstract]. In: Program and abstracts of the XV International AIDS Conference, 11-16 July 2004; Bangkok. Geneva: International AIDS Society; 2004. Abstract WeOrB1235.
21. Tremblay C, Merrill DP, Chou TC, et al. Two- and three-protease inhibitor combinations against zidovudine-sensitive and zidovudine-resistant HIV-1 isolates in vitro [abstract]. In: Program and abstracts of the 12th World AIDS Conference, 28 June - 3 July 1998; Geneva. Geneva: International AIDS Society; 1998. Abstract 41201.
22. St Clair MH, Millard J, Rooney J, et al. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res 1996; 29:53-56.
23. Furfine ES, Berrey MM, Naderer O, et al. Virologic and pharmacokinetic rationale for a new salvage regimen: APV/SQV/RTV BID [abstract]. Third International Workshop on Salvage Therapy for HIV Infection; 12-14 April 2000; Chicago. Report and Abstracts. Antivir Ther. 2000; 5 (Suppl 2): 1-35.
24. D'Aquila RT, Schapiro JM, Brun-Vezinet F, et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11:92-96.
25. Lexiva [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2003.
26. Sadler BM, Gillotin C, Lou Y, et al. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. Antimicrob Agents Chemother 2001; 45:3663-3668.
27. Corbett AH, Eron JJ, Fiscus SA, et al. The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr 2004; 36:921-928.
28. Boffito M, Dickinson L, Hill A, et al. Steady state pharmacokinetics of saquinavir hard gel/fosamprenavir 1000/700 plus 100 mg and 200 mg of ritonavir twice daily in HIV+ patients [abstract]. In: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2004; San Francisco. Alexandria: Foundation for Retrovirology and Human Health; 2004. Abstract 608.
29. Bertz R, Foit C, Ashbrenner E, et al. Effect of amprenavir on the steady-state pharmacokinetics of lopinavir/ritonavir in HIV+ and healthy subjects [abstract]. In: Program and Abstracts of 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 27-30 September 2002; San Diego. Washington DC: American Society for Microbiology; 2002. Abstract A-1823.
30. Mauss S, Schmutz G, Kuschak D. Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir? AIDS 2002; 16:296-297.
31. Khanlou H, Graham E, Farthing C. Drug interactions between amprenavir and lopinavir/ritonavir in salvage therapy. AIDS 2002; 16:797-798.
32. Raguin G, Chêne G, Morand-Joubert L, et al. Salvage therapy with lopinavir/ritonavir, amprenavir +/- an additional boost with ritonavir in HIV-infected patients with multiple treatment failure: Final 26-week results of Puzzle 1-ANRS104 study [abstract]. In: Program and Abstracts of 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 27-30 September 2002; San Diego. Washington DC: American Society for Microbiology; 2002. Abstract H-1078.
33. De Luca A, Baldini F, Cingolani A, et al. Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics. J Acquir Immune Defic Syndr 2004; 35:359-366. This provides interesting efficacy data on a complex double boosted protease inhibitor regimen, amprenavir/lopinavir/ritonavir, which can guide clinicians on the administration of these drugs.
34. Corbett AH, Davidson L, Park JJ, et al. Dose separation strategies to overcome the pharmacokinetic interaction of a triple protease inhibitor regimen containing fosamprenavir lopinavir, and ritonavir [abstract]. In: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2004; San Francisco. Alexandria: Foundation for Retrovirology and Human Health; 2004. Abstract 611.
35. Wire MB, Naderer OJ, Masterman AL, et al. The pharmacokinetic interaction between GW433908 and lopinavir/ritonavir (APV1001 land APV 10012) [abstract]. In: Program and Abstracts of the 11th Conference on Retroviruses and Opportunistic Infections, 8-11 February 2004; San Francisco. Alexandria: Foundation for Retrovirology and Human Health; 2004. Abstract 612.
36. Bell C, Hughes A, Asheret K, et al. Therapeutic drug monitoring (TDM) in patients taking fosamprenavir & kaletra as dual PI based antiretroviral therapy [abstract]. In: Program and abstracts of the XV International AIDS Conference, 11-16 July 2004; Bangkok. Geneva: International AIDS Society; 2004. Abstract TuPeB4618.
37. Back D, Blaschke T, Boucher C, et al. Optimising TDM in HIV clinical care: a practical guide to performing therapeutic drug monitoring (TDM) for antiretroviral agents. Version 1.0. 2003. http://www.hivpharmacology.com/. [Accessed 20th August 2004].
38. th Conference on Retroviruses and Opportunistic Infections, 10-14 February 2003; Boston. Alexandria: Foundation for Retrovirology and Human Health; 2003. Abstract 536.
39. Antoniou T, Tseng A, van Heeswijk R, et al. Steady-state pharmacokinetics (PK) and tolerability of indinavir (IDV) when co-administered with lopinavir/ritonavir (LPV/r) in experienced subjects [abstract]. In: Program and abstracts of 4th International Workshop on Clinical Pharmacology of HIV Therapy, 27-29 March 2003; Cannes. Utrecht: Virology Education; 2003. Abstract 8.10.
40. Bertz RG, Foit C, Ashbrenner E, et al. Assessment of the steady-state pharmacokinetic interaction of lopinavir/ritonavir with either indinavir or saquinavir in healthy subjects [abstract]. In: Program and abstracts of 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 27-30 September 2002; San Diego. Washington DC: American Society for Microbiology; 2002. Abstract A-1822.
41. Isaac A, Taylor S, Rubin G, et al. Lopinavir/ritonavir combined with twice-daily indinavir: pharmacokinetics in blood, CSF, and semen (The Protect Study) [abstract]. In: Program and abstracts of 10th Conference on Retroviruses and Opportunistic Infections, 10-14 February 2003; Boston. Alexandria: Foundation for Retrovirology and Human Health; 2003. Abstract 531.
42. Reyataz [package insert]. Priceton, NJ: Bristol Myer Squibb; 2004.
43. Huang L, Wring SA, Woolley JL, et al. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 2001; 29:754-760.
44. Gathe J, Kohlbrenner VM, Pierone G, et al. Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52 [abstract]. In: Program and abstracts of 10th Conference on Retroviruses and Opportunistic Infections, 10-14 February 2003; Boston. Alexandria: Foundation for Retrovirology and Human Health; 2003. Abstract 179.
45. Leith J, Walmsley S, Katlama C, et al. Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV) amprenavir (APV), or lopinavir (LPV): Interim analysis of BI1182.51 [abstract]. In: Program and abstracts of the 5th International Workshop on Clinical Pharmacology of HIV Therapy, 11-13 March 2004; Rome. Utrecht: Virology Education; 2004. Abstract 5.1.
46. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002; 16(Suppl 1):S5-S37.